Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 19/20 | 0.72 |
| ▸ | HDAC1 | Q13547 | 19/20 | 0.72 |
| ▸ | HDAC7 | Q8WUI4 | 19/20 | 0.72 |
| ▸ | HDAC11 | Q96DB2 | 19/20 | 0.72 |
| ▸ | HDAC8 | Q9BY41 | 19/20 | 0.72 |
| ▸ | HDAC6 | Q9UBN7 | 19/20 | 0.72 |
| ▸ | HDAC9 | Q9UKV0 | 19/20 | 0.72 |
| ▸ | HDAC5 | Q9UQL6 | 19/20 | 0.72 |
| ▸ | HDAC3 | O15379 | 18/20 | 0.72 |
| ▸ | HDAC2 | Q92769 | 18/20 | 0.72 |
| ▸ | HDAC10 | Q969S8 | 18/20 | 0.72 |
| ▸ | NCOR1 | O75376 | 2/20 | 0.72 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.72 |
| ▸ | BRD4 | O60885 | 1/20 | 0.72 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.72 |
| ▸ | EGFR | P00533 | 1/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.72 |
| ▸ | LTA4H | P09960 | 1/20 | 0.72 |
| ▸ | NR0B1 | P51843 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14934835 | 1.00 | HDAC4 (0.72) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL8178246 | 1.00 | HDAC4 (0.72) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL31203466 | 0.98 | HDAC4 (0.69) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL8132454 | 0.93 | HDAC4 (0.66) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL6669511 | 0.91 | HDAC4 (0.85) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL137348 | 0.91 | HDAC4 (0.85) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL1065393 | 0.91 | HDAC4 (0.85) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL6665592 | 0.91 | HDAC4 (0.85) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL517309 | 0.89 | HDAC4 (0.81) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| Hydroxyamine SCHEMBL1268824 | 0.87 | HDAC6 (0.79) | HDAC4HDAC1HDAC7HDAC11HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360089-A1 | Metabolically Stable HDAC Inhibitors with Trifluoromethylpyruvamide as Metal-Binding Group | THE UNIVERSITY OF TOLEDO (US) | 2024-10-31 | — | — | US | disclosed |
| WO-2013066836-A1 | COMPOUNDS AND METHODS | GLAXOSMITHKLINE LLC (US) | 2013-05-10 | — | — | WO | disclosed |
| US-7345174-B2 | Cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2008-03-18 | — | — | US | disclosed |
| US-7345174-B2 | Cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2008-03-18 | — | — | US | disclosed |
| US-7345174-B2 | Cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2008-03-18 | — | — | US | disclosed |
| CN-101048374-A | Mercaptoamides as histone deacetylase inhibitors | OSI PHARM INC (US) | 2007-10-03 | — | — | CN | disclosed |
| EP-1794117-A2 | MERCAPTOAMIDES AS HISTONE DEACETYLASE INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2007-06-13 | — | — | EP | disclosed |
| US-20070010536-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2007-01-11 | — | — | US | disclosed |
| US-20070010536-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2007-01-11 | — | — | US | disclosed |
| US-20070010536-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2007-01-11 | — | — | US | disclosed |
| EP-1231919-A2 | NOVEL CLASS OF CYTODIFFERENTIATING AGENTS AND HISTONE DEACETYLASE INHIBITORS, AND METHODS OF USE THEREOF | Sloan-Kettering Institute For Cancer Research (US) | 2002-08-21 | — | — | EP | disclosed |
| WO-2001018171-A2 | NOVEL CLASS OF CYTODIFFERENTIATING AGENTS AND HISTONE DEACETYLASE INHIBITORS, AND METHODS OF USE THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2001-03-15 | — | — | WO | disclosed |
| EP-1044979-A2 | 1-[(N-(un)substituted)amidoalkyl]spiroindolinonaphthoxazines, their preparation, compositions and (co)polymer matrices containing them | Corning S.A. (FR) | 2000-10-18 | — | — | EP | disclosed |
| EP-0660832-B1 | SEROTONIN RECEPTOR AGENTS | MERRELL PHARMA INC (US) | 1998-01-14 | — | — | EP | disclosed |
| US-5436246-A | Compounds for treatment of anxiety, depression, migraine, stroke, angina and hypertension | MERRELL DOW PHARMACEUTICALS INC. | 1995-07-25 | — | — | US | disclosed |
| EP-0660832-A1 | SEROTONIN RECEPTOR AGENTS | MERRELL PHARMACEUTICALS INC. (US) | 1995-07-05 | — | — | EP | disclosed |
| WO-1994006789-A1 | SEROTONIN RECEPTOR AGENTS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-03-31 | — | — | WO | disclosed |
| EP-0150168-B1 | USE OF METAL SALTS OF THIOSULPHURIC -S-ESTERS AS RUBBER/METAL BONDING PROMOTERS | MONSANTO EUROPE S.A./N.V. (BE) | 1991-05-08 | — | — | EP | disclosed |
| US-4581297-A | STEEL BELTED RADIAL TIRES | MONSANTO EUROPE, S.A. (BE) | 1986-04-08 | — | — | US | disclosed |
| EP-0150168-A2 | Use of metal salts of thiosulphuric -S-esters as rubber/metal bonding promoters | MONSANTO EUROPE S.A./N.V. (BE) | 1985-07-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360089-A1 | Metabolically Stable HDAC Inhibitors with Trifluoromethylpyruvamide as Metal-Binding Group | HDAC1, HDAC3, HDAC2 | HDAC4 4/4885HDAC1 1/4885HDAC7 10/4885 |
| US-20070010536-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | ACIN1, HDAC3, HDAC1 | HDAC4 6/4885HDAC1 3/4885HDAC7 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.